$166.08
-0.06 (-0.04%)
AZN News30 articles
FTSE 100 Rises as FTSE 250 Slips, Signaling Narrow Market Rally
The FTSE 100 edged higher on Monday, but the FTSE 250 fell, underscoring a narrow rally driven by defensive stocks and oil producers rather than broad market strength.
AstraZeneca's SERENA-4 Flop Limits Etcamah's First-Line Reach
AstraZeneca's SERENA-4 trial failed to show a significant PFS benefit for Etcamah in first-line breast cancer, narrowing its commercial opportunity to ESR1-mutant patients.
Roche Jumps on $9B Breast Cancer Drug Forecast
Roche shares gained 1.5% after Morgan Stanley forecast CHF9B peak sales for its breast cancer drug giredestrant, a bullish signal for the pharma giant.
Asia Markets Steady as Oil Holds Gains; Singapore Dollar, Meta, Aurizon in Focus
Asian shares were muted as oil prices held gains on Middle East tensions. Singapore dollar strengthened on robust export data. Meta's cash flow dropped 91% as AI spending surged. Aurizon and others reported results.
Moderna's mRNA Flu Shot Wins FDA Nod, But Sales Loom
Moderna secured FDA approval for its mRNA flu vaccine, but analysts see minimal revenue impact until late 2027, as the company's cash burn continues.
Bristol Myers Unveils $2.3B Houston Facility for Flexible Drug Production
Bristol Myers Squibb (BMY) will build a $2.3 billion drug-manufacturing campus in Houston, supporting small molecules, biologics, and antibody-drug conjugates, with nearly 500 skilled jobs.
Bristol Myers Soars on AstraZeneca Takeover Talks, But Market Cap Math Raises Red Flags
Bristol Myers Squibb (BMY) surged 8% on AstraZeneca (AZN) merger speculation, but combined market cap fell $6.2B. Strong Q2 results and raised guidance bolster standalone case.
AstraZeneca slides on Bristol Myers tie-up talks; $5B value gap emerges
AstraZeneca shares dropped 5% on report of early merger talks with Bristol Myers Squibb, which gained 6% premarket. Combined market value fell about $5.2 billion.
Bristol Myers Squibb at Crossroads as AstraZeneca Merger Talks Surface
Bristol Myers Squibb shares rose 5.2% last week after strong Q2 earnings, but a reported $400B merger approach from AstraZeneca puts the stock in focus Monday.
AZN-BMY Merger Talks: A $455B Pharma Mega-Deal in the Making?
AstraZeneca and Bristol Myers Squibb are reportedly in merger talks, which could create a $455 billion pharmaceutical giant. Reuters has not confirmed the report.
Tempus AI Dips After Hours Despite Q2 Beat; Focus Shifts to H2 Profitability
Tempus AI slipped 2.6% in after-hours trade despite a slight Q2 revenue beat and raised full-year guidance, as markets scrutinize the company's ability to ramp margins in the second half.
FTSE 100 Gains Trimmed as Oil Price Slide Spurs Sector Rotation
London's FTSE 100 trimmed most of its early gains as a sharp drop in oil prices fueled a sector rotation, benefiting airlines and mid-caps while pressuring energy majors.
FTSE 100 Gains as Oil Earnings and BoE Decision Loom
The FTSE 100 closed at 10,736.23, up 1.28% for the week. Energy is expected to contribute 62% of incremental earnings growth for the STOXX 600, with the BoE widely anticipated to hold rates steady.
GSK faces £3.6B revenue gap ahead of Tuesday strategy update
GSK faces a £3.63 billion revenue gap versus its 2031 target of £40 billion ahead of its strategy update on July 28. The shortfall persists despite oncology growth.
SK Hynix Market Cap Plunges 114 Trillion Won Amid Legal Woes and Tech Sell-Off
SK Hynix shares tumbled 8.34% on Friday, erasing 114 trillion won in market value, as a court order against chairman Chey Tae-won added to a broader tech rout.
Aviva's 6% Yield and Strategic Growth Drive UK Market Focus
Aviva offers a 6% dividend yield with rising payouts, while Middle East tensions boost energy stocks and gold prices. U.S. futures edge up ahead of tech earnings.
Attovia Therapeutics Files IPO to Challenge Dupixent and Nemluvio
Attovia Therapeutics has filed for an IPO to raise capital for developing rival treatments to Sanofi and Regeneron's Dupixent and Galderma's Nemluvio.
FTSE 100 Edges Lower as AstraZeneca, HSBC Drag; Energy Stocks Rally
The FTSE 100 dipped 0.1% to 10,486 as AstraZeneca and HSBC losses outweighed gains from BP and Shell. Housing stocks rose on Help to Buy rumors.
Pfizer Gains FDA Nod for Padcev Combo, Yet Stock Remains Flat
Pfizer's Padcev/Keytruda combo gets FDA approval for bladder cancer, but the stock dipped 0.33%. Wall Street remains cautious about revenue impact.
Biotech Sector Hit by $15B Loss as Vertex, Ionis Stumble
Vertex and Ionis shares slumped after setbacks, erasing $14.8B in market cap. Crinetics, BridgeBio, and Vera gained $6.1B combined.
Vodafone and easyJet Deal Surge Lifts FTSE
Vodafone and easyJet shares surged on separate deal announcements, lifting the FTSE 100 and FTSE 250 while most stocks remained flat.
Ionis Plunges 23% After Wainua Misses Key Goal in Heart Disease Trial
Ionis stock tumbled 23% after Wainua missed its primary endpoint in a major heart disease trial, erasing $3.2 billion in market value. The setback shifts attention to the company's TRYNGOLZA launch.
FTSE 100 Dips as AstraZeneca Drug Trial Disappoints
London's FTSE 100 fell as AstraZeneca dropped nearly 9% on a trial miss. The FTSE 250 rose, splitting the market. Oil and Middle East risks persist.
Novo Nordisk Shares Rally as Healthcare Sector Lifts OMXC25
Novo Nordisk B shares rose 5% to 294.4 Danish crowns, leading the OMXC25 higher as healthcare stocks gained. The rally came amid a cyber incident and ongoing competition with Eli Lilly in oral obesity drugs.
G7 Leaders Debate AI Model Access Amid OpenAI's $1T IPO Plan and Rising China Competition
G7 leaders debate AI model access as OpenAI files for a $1T IPO. Anthropic restricts models, China boosts local AI, and cybersecurity deals surge.
GSK Acquires Nuvalent for $10.6B in Oncology Push Ahead of HIV Patent Cliff
GSK buys Nuvalent for $10.6B, paying a 40% premium, to strengthen its oncology portfolio and offset upcoming HIV drug patent losses.
Novo Nordisk Shares Slide 4% Despite Wegovy Pill Prescriptions Surpassing 3 Million
Novo Nordisk shares dropped over 4% despite the Wegovy pill hitting 3 million U.S. prescriptions, as investors weighed profit margins against fierce competition from Eli Lilly and AstraZeneca.
Merck Shares Jump as New Drug Data Eases Keytruda Concerns
Merck shares surged 4.9% to $120.26 after ASCO data showed its new cancer drug sac-TMT combined with Keytruda improved progression-free survival, reinforcing confidence in the post-Keytruda pipeline.
Abivax shares drop despite positive Phase 3 results for ulcerative colitis drug
Abivax shares plunged 33.7% after hours despite obefazimod achieving clinical remission in over 50% of patients in a Phase 3 trial. The company plans to submit an FDA application in late Q4 2026.
AIM ImmunoTech Surges on Early Pancreatic Cancer Trial Enrollment Completion
AIM ImmunoTech shares surged over 100% after its Phase 2 pancreatic cancer trial reached final enrollment ahead of schedule, with the primary endpoint readout set for December 2026.